Sandu Pharma.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE751D01014
NSEID:
BSEID: 524703
View on BSE

INR

39.48

-0.32 (-0.8%)

BSENSE

Aug 11, 01:26 PM

BSE+NSE Vol: 939

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Roopa Industries

Murae Organisor

Parmax Pharma

Guj. Terce Labs.

Sandu Pharma.

Welcure Drugs

Lasa Supergeneri

Medi Caps

Goldline Pharmac

Chandra Bhagat

Medicamen Organ.

Why is Sandu Pharmaceuticals Ltd ?

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 3.73%

Poor long term growth as Net Sales has grown by an annual rate of 3.54% and Operating profit at 7.49% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.92

Flat results in Mar 26

EPS(Q) Lowest at Rs 0.04

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -20.48% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sandu Pharma. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Sandu Pharma.

-20.48%

-0.46

44.85%

Sensex

-3.04%

-0.23

13.54%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.54%

EBIT Growth (5y)

7.49%

EBIT to Interest (avg)

1.92

Debt to EBITDA (avg)

0.14

Net Debt to Equity (avg)

-0.05

Sales to Capital Employed (avg)

1.63

Tax Ratio

27.91%

Dividend Payout Ratio

49.90%

Pledged Shares

Institutional Holding

0.01%

ROCE (avg)

4.94%

ROE (avg)

3.73%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.92

EV to EBIT

17.44

EV to EBITDA

13.19

EV to Capital Employed

0.91

EV to Sales

0.54

PEG Ratio

1.92

Dividend Yield

2.01%

ROCE (Latest)

5.22%

ROE (Latest)

3.71%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company

NO KEY POSITIVE TRIGGERS

-1What is not working for the Company

EPS(Q)

Lowest at Rs 0.04

Loading Valuation Snapshot...

Here's what is not working for Sandu Pharma.

Earnings per Share (EPS) - Quarterly

Lowest at Rs 0.04

in the last five quarters

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (Rs)